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Race and Risk of Subsequent Aggressive Breast Cancer
Following Ductal Carcinoma in Situ
Ying Liu, MD, PhD

1,2

; Robert West, MD3; Jason D. Weber, PhD2,4; and Graham A. Colditz, MD, DrPH1,2

BACKGROUND: General populations of black women have a higher risk of developing breast cancer negative for both estrogen
receptor (ER) and progesterone receptor (PR) in comparison with white counterparts. Racial differences remain unknown in the
risk of developing aggressive invasive breast cancer (IBC) that is characterized by negativity for both ER and PR (ER–PR–) or higher
21-gene recurrence scores after ductal carcinoma in situ (DCIS). METHODS: This study identified 163,892 women (10.5% black, 9.8%
Asian, and 8.6% Hispanic) with incident DCIS between 1990 and 2015 from the Surveillance, Epidemiology, and End Results data
sets. Cox proportional hazards regression was used to estimate hazards ratios (HRs) of subsequent IBC classified by the hormone
receptor status and 21-gene recurrence scores. RESULTS: During a median follow-up of 90 months, 8333 women developed IBC. In
comparison with white women, the adjusted HR of subsequent ER–PR– breast cancer was 1.86 (95% confidence interval [CI], 1.572.20) for black women (absolute 10-year difference, 2.2%) and 1.40 (95% CI, 1.14-1.71) for Asian women (absolute 10-year difference,
0.4%); this was stronger than the associations for ER+ and/or PR+ subtypes (Pheterogeneity = .0004). The 21-gene recurrence scores
of subsequent early-stage, ER+ IBCs varied by race/ethnicity (Pheterogeneity = .057); black women were more likely than white women
to have a recurrence score of 26 or higher (HR, 1.38; 95% CI, 1.00-1.92). No significant difference was observed in the risks of subsequent IBC subtypes for Hispanic women. CONCLUSIONS: Black and Asian women with DCIS had higher risks of developing biologically aggressive IBC than white counterparts. This should be considered in treatment decisions for black and Asian patients with
DCIS. Cancer 2019;125:3225-3233. © 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer
Society. This is an open access article under the terms of the Creative Commons Attribution -NonCommercial-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no
modifications or adaptations are made.
KEYWORDS: breast cancer, ductal carcinoma in situ, race, recurrence.

INTRODUCTION
Ductal carcinoma in situ (DCIS), a nonobligate precursor to invasive breast cancer (IBC),1 currently constitutes
20% to 30% of mammographically detected breast tumors.2,3 Approximately 64,000 new DCIS cases were expected
to be diagnosed in the United States in 2018.2 Although the 10-year survival rate is higher than 98%,4 more than 10%
of patients with DCIS develop a second breast tumor within 10 years of their diagnosis, and half of these are invasive.3
We and others have demonstrated a significant variation by race and ethnicity in the risk of developing breast
cancer after DCIS. Compared with white women, black women are more likely to have second tumors (invasive and
noninvasive) in either breast and die of IBC after DCIS.5-11 An increased risk of ipsilateral breast tumors has been
observed in Hispanic women with DCIS,5,12 and an increased risk of contralateral breast tumors has been identified in
Asian women with DCIS.5
In addition, our prior studies showed a higher proportion of estrogen receptor–positive (ER+) DCIS subtypes in
black women than white women.5,6 However, black women with IBC who have no prior history of DCIS are far more
likely than white counterparts to present with biologically aggressive features, including a lack of ER, progesterone
receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and high RNA expression–based
recurrence scores.13-15 It remains unknown whether black race (compared with white race) is associated with a higher
risk of subsequently developing biologically aggressive breast cancer in patients with DCIS. In a large, racially diverse
population of women with DCIS, we examined the risks of subsequent IBC subtypes, characterized by hormone receptor status and 21-gene recurrence scores, by race and ethnicity.
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MATERIALS AND METHODS
Patient Population

Women with unilateral DCIS diagnosed between January
1990 and June 2015 (n = 211,439) were identified from
the 17 Surveillance, Epidemiology, and End Results
(SEER) registries.12 The Alaska Native Tumor Registry
was excluded because of the small number of Alaskan
Native patients. A data-use agreement form was required
before access to the deidentified data set. Because the deidentified data were used, approval from the institutional
review board of Washington University in St. Louis and
patients’ informed consent were not required.
We excluded patients with a prior cancer history
(n = 41,912) and those younger than 20 years (n = 19).
Approximately 97% of eligible cases were white, black,
Asian (not including Pacific Islanders), or Hispanic; thus,
women of other races or unknown race (n = 5616) were
excluded if they were non-Hispanic. The final sample size
was 163,892. In the analysis of ipsilateral breast cancer,
we also excluded patients treated with mastectomy for
DCIS and those whose surgical treatment was unknown
(n = 47,253). Women treated with prophylactic mastectomy at initial DCIS (n = 9638) were also excluded
from the analysis of contralateral breast cancer. Race and
ethnicity were classified as non-Hispanic white (white),
non-Hispanic black (black), non-Hispanic Asian (Asian),
or Hispanic. Filipinos, Chinese, and Japanese were the
3 largest Asian subgroups and accounted for 63.4% of
Asian patients. The majority of the Hispanics (95.5%)
were white, and thus Hispanic whites and Hispanic nonwhites were combined into a single group.

DCIS was categorized as no surgical treatment, breastconserving surgery alone, breast-conserving surgery plus
radiation therapy, mastectomy, or unknown.
Outcomes

Subsequent breast cancer included IBC (reported to
SEER registries) in either breast or metastatic breast cancer diagnosed at least 6 months after the initial DCIS.
Ipsilateral IBCs were further classified as invasive recurrences arising in the same quadrant as the original DCIS
and IBCs developing elsewhere in that same breast.17
Theoretically, the latter have the same incidence and
characteristics as IBCs developing in the contralateral
breast. Thus, IBCs arising in the ipsilateral breast away
from the original DCIS and in the contralateral breast
were combined. IBC subtypes were similarly defined by
both ER and PR. For IBC cases diagnosed between 2004
and 2015, SEER data were linked to 21-gene recurrence
score assay results from Genomic Health, Inc (Redwood
City, California), by Information Management Services
(Calverton, Maryland).18 IBC recurrence scores were
categorized as low-risk (scores <18), intermediate-risk
(scores = 18-30), or high-risk (scores ≥31).13-15 Because
of the small number of racial minority patients who had
21-gene recurrence scores, we combined intermediateand high-risk scores. A prospective trial (Trial Assigning
Individualized Options for Treatment [TAILORx])
has demonstrated that chemotherapy does not benefit
patients with early-stage, hormone receptor–positive IBC
whose 21-gene recurrence scores are less than 26.19 We
also dichotomized recurrence scores with a cutoff of 26.

Covariates

Statistical Analysis

Demographic factors included the age (20-39, 40-49,
50-59, 60-69, or 70-84 years) and year of DCIS diagnosis (1990-1999, 2000-2009, or 2010-2015) and registries.
Histopathological features of DCIS included the tumor
size (<2 cm, 2-5 cm, ≥5 cm, or unknown), grade (well
differentiated, moderately differentiated, poorly differentiated, or unknown), and histologic pattern (comedo,
papillary, cribriform, solid, or not otherwise specified).
Tumor size was also categorized with the cutoffs of 1 and
5 cm, and the results were similar (Supporting Table 1).
Consistent with the literature,16 tumors were considered
to be ER+ if the immunohistochemistry results of ER
were positive or borderline. PR+ DCIS was similarly
defined. Tumors positive for ER and/or PR were classified as hormone receptor–positive (ER+/PR+), and
tumors negative for both ER and PR were classified as
hormone receptor–negative (ER–PR–). Treatment for

Baseline characteristics across racial/ethnic groups were
compared with Pearson chi-square tests for categorical
variables and with an analysis of variance for continuous variables. Cox proportional hazards regression was
used to compute race-associated hazard ratios (HRs)
and 95% confidence intervals (CIs) for subsequent IBC
subtypes, and they were adjusted for the receptor status
in the initial DCIS and the aforementioned covariates.
Person-years were calculated from 6 months after the initial DCIS to the date of subsequent breast cancer, death,
or December 31, 2015, whichever occurred first. A missing ER and PR status for subsequent IBC was considered for censoring. The assumption of proportionality
for Cox models was confirmed with scaled Schoenfeld
residuals. To determine whether race/ethnicity was differentially associated with IBC subtypes, an extension of
the Cox proportional hazards regression models was used
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to estimate the separate associations of race/ethnicity
with the relative hazard of each subtype. Specifically, we
used the approach proposed by Lunn and McNeil,20,21
in which each patient had a separate observation for
each type of outcome and the analysis was stratified on
outcome types. The initial full model assumed different
associations of race/ethnicity and covariates with IBC
subtypes. In a reduced model, race/ethnicity was constrained to have a single estimate across cancer subtypes,
and the effects of covariates were allowed to be different. Likelihood ratio tests for heterogeneity were used to
determine statistically significant differences in the associations of race/ethnicity with cancer subtypes. All statistical analyses were performed with SAS (version 9.4; SAS
Institute, Cary, North Carolina). Statistical significance
was assessed as a 2-sided P value < .05.
HER2 data were collected for breast cancers diagnosed after 2009. A secondary analysis was performed to
compare the risks of subsequent IBC classified by ER,
PR, and HER2. Subsequent breast cancers occurring
before 2010 were analyzed as censoring.
RESULTS
Among 163,892 women with DCIS, 71.0% were nonHispanic white, 10.5% were non-Hispanic black, 9.8%
were non-Hispanic Asian, and 8.6% were Hispanic.
Compared with white women, racial/ethnic minority women were younger at the initial DCIS and were
more likely to have large, well-to-moderately differentiated, noncomedo lesions (each P value < .0001; Table 1).
Black and Asian women underwent mastectomy more
frequently than white and Hispanic women (P < .0001).
The ER and PR status for the initial DCIS was available for 60.3% and 56.8% of cases, respectively. The frequency of ER–PR– DCIS was lower in the black group
(11.4%) than other racial groups (white, 14.2%; Asian,
13.8%; Hispanic, 13.4%; P < .0001; Table 1).
During a median follow-up of 90 months, 8333
women developed IBC in either breast or metastatic
breast cancer, and 7746 of these women (93.0%) had the
ER and/or PR status available for their IBC. In comparison with white women, the overall risk of subsequent IBC
was significantly increased in black women (HR, 1.42;
95% CI, 1.32-1.52; absolute 10-year risk difference, 2.2%;
95% CI, 1.7%-2.7%) but not in Asian women (HR,
1.08; 95% CI, 0.99-1.17; absolute 10-year risk difference,
0.4%; 95% CI, –0.1% to 0.8%) or Hispanic women (HR,
1.09; 95% CI, 1.00-1.18; absolute 10-year risk difference,
0.5%; 95% CI, 0%-1.0%). The associations were much
stronger for ER–PR– subtypes than ER+/PR+ subtypes
Cancer  
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(Pheterogeneity = .0004; Table 2). In comparison with white
women, the multivariable-adjusted HR of ER–PR– IBC
was 1.86 (95% CI, 1.57-2.20) in black women, 1.40
(95% CI, 1.14-1.71) in Asian women, and 1.24 (95% CI,
1.00-1.54) in Hispanic women. Black women also had
a significantly higher risk of subsequent triple-negative
(negative for ER, PR, and HER2) breast cancer (HR,
1.99; 95% CI, 1.44-2.75), and Asian women had a significantly higher risk of subsequent HER2+ breast cancer (HR, 1.85; 95% CI, 1.21-2.84; Supporting Table 2).
We further examined the risks separately for ipsilateral and contralateral IBC by race/ethnicity (Table 2).
In comparison with white women, the risk of ipsilateral
IBC was significantly higher in black (HR, 1.65; 95% CI,
1.49-1.83; absolute 10-year risk difference, 2.1%; 95% CI,
1.6%-2.6%), Asian (HR, 1.23; 95% CI, 1.09-1.38; absolute 10-year risk difference, 0.7%; 95% CI, 0.3%-1.2%),
and Hispanic women (HR, 1.19; 95% CI, 1.05-1.35; absolute 10-year risk difference, 0.6%; 95 CI, 0.2%-1.1%).
There was no significant heterogeneity in the associations
for risks of ipsilateral cancer subtypes (Pheterogeneity = .57;
Table 2). The multivariable-adjusted HR for ipsilateral
ER–PR– subtypes was 1.83 (95% CI, 1.43-2.35) in black
women, 1.34 (95% CI, 0.99-1.81) in Asian women, and
1.40 (95% CI, 1.05-1.87) in Hispanic women.
In comparison with white women, the risk of
contralateral IBC was significantly increased in black
women (HR, 1.18; 95% CI, 1.07-1.31; absolute 10-year
risk difference, 0.6%; 95% CI, 0.2%-0.9%). This association was much stronger for ER–PR– subtypes (HR,
1.97; 95% CI, 1.55-2.52) than ER+/PR+ subtypes (HR,
1.07; 95% CI, 0.95-1.20; Pheterogeneity < .0001). Although
the risk of overall contralateral IBC was similar between
Asian and white women (HR, 0.97; 95% CI, 0.86-1.10;
absolute 10-year risk difference, 0.1%; 95% CI, –0.4%
to 0.3%), Asian women had a significantly higher risk of
ER–PR– subtypes (HR, 1.61; 95% CI, 1.20-2.16). The
risks of overall contralateral breast cancer and subtypes
were all comparable between Hispanic and white women.
Subsequent breast cancers were also categorized on
the basis of both the laterality and locations of the original DCIS and subsequent IBC (Table 3). Among 3010
cases with known locations for both the original DCIS
and subsequent ipsilateral IBC, 21.4% developed IBC
in the same quadrant of the same breast as the original DCIS. Compared with white women, black women
had significantly higher risks of developing IBC in the
same quadrant of the same breast as the original DCIS
(HR, 1.51; 95% CI, 1.18-1.93; absolute 10-year risk
difference, 0.3%; 95% CI, 0.1%-0.5%) and IBC in the
3227
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TABLE 1. Age and Age-Standardized Characteristics of Women With Unilateral DCIS in SEER by Race and
Ethnicity (n = 163,892), 1990-2015

No. of cases
Age, mean (SD), y
Age at diagnosis, %
20-39 y
40-49 y
50-59 y
60-69 y
≥70 y
Length of follow-up, median (range), mo
Length of follow-up, %
6-11 mo
12-59 mo
60-119 mo
≥120 mo
Year of first DCIS diagnosis, %
1990-1999
2000-2009
2010-2015
Histologic subtype, %
Not otherwise specified
Comedo
Papillary
Cribriform
Solid
Grade, %
Well differentiated
Moderately differentiated
Poorly differentiated
Tumor size, %
<2.0 cm
2.0-4.9 cm
≥5.0 cm
ER, %
Negative
Positive
PR, %
Negative
Positive
Hormone receptor status, %
ER– and PR–
ER+ or PR+
Treatment for primary DCIS, %
No surgery
BCS alone
BCS and radiation
Mastectomy

White

Black

Asian

Hispanic

Pa

116,431
59.5 (12.4)

17,274
58.3 (12.2)

16,039
56.4 (11.7)

14,148
56.2 (11.8)

<.0001

3.1
20.9
27.8
24.9
23.3
95 (6-311)

4.4
21.5
29.2
25.5
19.5
79 (6-311)

4.5
27.5
30.0
22.8
15.2
83 (6-311)

4.8
28.1
29.9
21.9
15.3
75 (6-311)

<.0001
<.0001

3.3
27.0
31.3
38.4

4.8
33.8
32.5
28.8

5.0
32.0
30.9
32.1

5.9
35.1
31.9
27.2

<.0001

17.0
53.3
29.7

12.7
49.9
37.4

14.3
48.3
37.5

10.1
49.3
40.6

<.0001

66.9
13.5
5.2
8.5
5.9

68.4
11.4
7.0
8.2
5.0

67.5
11.8
5.0
10.0
5.8

68.3
11.6
5.4
9.4
5.3

<.0001

13.7
40.0
46.3

16.6
43.3
40.1

14.1
43.3
42.6

14.3
43.6
42.1

<.0001

75.3
19.2
5.5

69.9
21.8
8.3

69.2
24.9
5.9

70.0
22.8
7.2

<.0001

15.9
84.1

12.9
87.1

15.5
84.5

14.9
85.1

<.0001

26.1
73.9

21.9
78.1

23.9
76.1

24.7
75.3

<.0001

14.2
85.8

11.4
88.6

13.8
86.2

13.4
86.6

<.0001

2.2
24.7
44.3
28.9

3.4
23.4
43.6
29.5

2.1
23.0
44.0
31.0

3.0
26.2
43.7
27.1

<.0001

Abbreviations: BCS, breast-conserving surgery; DCIS, ductal carcinoma in situ; ER, estrogen receptor; PR, progesterone receptor; SD, standard deviation;
SEER, Surveillance, Epidemiology, and End Results.
Race and ethnicity were classified into mutually exclusive categories: non-Hispanic white (hereafter called white), non-Hispanic Black (black), non-Hispanic
Asian (Asian), and Hispanic (Hispanic). Supporting Table 6 shows distributions of missing values for each variable across race groups. Due to rounding, percentages did not always add up to 100%.
a
P values were calculated from comparisons across all groups except for groups with missing values.

ipsilateral breast away from the original DCIS and in
the contralateral breast (HR, 1.34; 95% CI, 1.24-1.45;
absolute 10-year risk difference, 1.5%; 95% CI, 1.1%2.0%). The increased risk of IBC in the ipsilateral
breast away from the original DCIS and in the contralateral breast was much stronger for ER–PR– subtypes (HR, 1.93; 95% CI, 1.60-2.40) than ER+/PR+
subtypes (HR for ER+/PR+, 1.24; 95% CI, 1.13-1.36)
3228

in black women (Pheterogeneity < .0001). In comparison
with white women, the risk was significantly increased
for ER–PR– IBC developing in the ipsilateral breast
away from the original DCIS and in the contralateral
breast in Asian women (HR, 1.45; 95% CI, 1.15-1.82)
but not for ER+/PR+ subtypes (HR, 0.99; 95% CI,
0.89-1.10). There was no significant difference in the
risk of developing IBC in the same quadrant of the
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TABLE 2. Adjusted HRs of Subsequent IBC Classified by Laterality and Hormone Receptor Status
According to Race and Ethnicity in Women With DCIS in SEER, 1990-2015
All Second Invasive Eventsa

ER+ or PR+

ER– and PR–

Person-y

Cases, No.

HRb (95% CI)

Cases, No.

HRb (95% CI)

Cases, No.

HRb (95% CI)

White
Black
Asian
Hispanic

1,018,475
129,931
128,657
102,614

5884
1002
807
640

1.00
1.42 (1.32-1.52)
1.08 (0.99-1.17)
1.09 (1.00-1.18)

4653
720
620
505

1.00
1.31 (1.21-1.43)
1.01 (0.92-1.11)
1.09 (0.99-1.20)

821
190
135
102

Ipsilateral IBCd

White
Black
Asian
Hispanic

709,275
89,081
86,294
72,785

2438
478
378
309

1.00
1.65 (1.49-1.83)
1.23 (1.09-1.38)
1.19 (1.05-1.35)

1846
341
286
235

1.00
1.58 (1.40-1.78)
1.19 (1.03-1.36)
1.20 (1.04-1.38)

393
86
61
59

Contralateral IBCe

White
Black
Asian
Hispanic

971,003
126,291
125,104
98,900

3134
446
396
292

1.00
1.18 (1.07-1.31)
0.97 (0.86-1.10)
0.98 (0.87-1.11)

2556
322
306
234

1.00
1.07 (0.95-1.20)
0.89 (0.78-1.02)
0.97 (0.84-1.11)

363
92
68
38

1.00
1.86 (1.57-2.20)
1.40 (1.14-1.71)
1.24 (1.00-1.54)
P heterogeneity = .0004
1.00
1.83 (1.43-2.35)
1.34 (0.99-1.81)
1.40 (1.05-1.87)
P heterogeneity = .57
1.00
1.97 (1.55-2.52)
1.61 (1.20-2.16)
1.13 (0.80-1.60)
P heterogeneity < .0001

Subsequent IBC

c

Abbreviations: CI, confidence interval; DCIS, ductal carcinoma in situ; ER, estrogen receptor; IBC, invasive breast cancer; HR, hazard ratio; PR, progesterone
receptor; SEER, Surveillance, Epidemiology, and End Results.
a
Second IBCs included those positive for ER or PR (ER+ or PR+), those negative for both ER and PR (ER–PR–), and those with no information on ER and PR.
b
HRs were adjusted for the following: age (20-39, 40-49, 50-59, 60-69, or ≥70 years) and year of the primary DCIS diagnosis (1990-1999, 2000-2009, or 20102015); registry; treatment for primary DCIS (no surgical treatment, breast-conserving surgery alone, breast-conserving surgery followed by radiation therapy,
mastectomy, or unknown); and histopathological features of primary DCIS, including the tumor size (<2 cm, 2-5 cm, ≥5 cm, or unknown), grade (well differentiated, moderately differentiated, poorly differentiated, or unknown), histology (comedo, papillary, cribriform, solid, or not otherwise specified), and hormone
receptor expression (positive, negative, or unknown).
c
Subsequent IBCs included ipsilateral IBCs, contralateral IBCs, and subsequent metastatic breast cancers.
d
The analysis included the patients who had been treated with breast-conserving surgery or no surgical treatment for their primary DCIS.
e
Patients who had undergone bilateral mastectomy for their primary DCIS were excluded.

TABLE 3. Adjusted HRs of Developing IBC in the Same Quadrant of the Same Breast as the Original DCIS
and IBC in the Ipsilateral Breast Away From the Original DCIS or the Contralateral Breast According
to Race and Ethnicity in Women With DCIS in SEER, 1990-2015
All Second Invasive Eventsa
Person-y

ER+ or PR+

b

Cases, No. HR (95% CI) Cases, No.

ER– and PR–

b

HR (95% CI) Cases, No.

IBC in ipsilateral breast
away from original DCIS
and in contralateral
breast

White
Black
Asian
Hispanic

971,003
126,291
125,104
98,900

4741
755
648
489

1.00
1.34 (1.24-1.45)
1.06 (0.97-1.17)
1.05 (0.95-1.16)

3776
547
497
388

1.00
1.24 (1.13-1.36)
0.99 (0.89-1.10)
1.05 (0.94-1.17)

630
149
107
71

IBC in same quadrant of
same breast as original
DCIS

White
Black
Asian
Hispanic

709,275
89,081
86,294
72,785

431
83
71
60

1.00
1.51 (1.18-1.93)
1.15 (0.87-1.52)
1.16 (0.88-1.54)

327
63
55
47

1.00
1.47 (1.10-1.95)
1.16 (0.84-1.59)
1.22 (0.89-1.67)

62
11
13
12

HRb (95% CI)
1.00
1.93 (1.60-2.40)
1.45 (1.15-1.82)
1.14 (0.88-1.47)
P heterogeneity < .0001
1.00
1.48 (0.75-2.90)
1.49 (0.75-2.98)
1.63 (0.85-3.13)
P heterogeneity = .80

Abbreviations: CI, confidence interval; DCIS, ductal carcinoma in situ; ER, estrogen receptor; HR, hazard ratio; IBC, invasive breast cancer; PR, progesterone
receptor; SEER, Surveillance, Epidemiology, and End Results.
a
Second IBCs included those positive for ER or PR (ER+ or PR+), those negative for both ER and PR (ER–PR–), and those with no information on ER and PR.
b
Hazard ratios were adjusted for the following: age (20-39, 40-49, 50-59, 60-69, or ≥70 years) and year of the primary DCIS diagnosis (1990-1999, 2000-2009,
or 2010-2015); registry; treatment for primary DCIS (no surgical treatment, breast-conserving surgery alone, breast-conserving surgery followed by radiation
therapy, mastectomy, or unknown); and histopathological features of primary DCIS, including the tumor size (<2 cm, 2-5 cm, ≥5 cm, or unknown), grade (well
differentiated, moderately differentiated, poorly differentiated, or unknown), histology (comedo, papillary, cribriform, solid, or not otherwise specified), and
hormone receptor expression (positive, negative, or unknown).

same breast as the original DCIS, in a different quadrant of the same breast, or in the contralateral breast
between Hispanic and white women.
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Among 5045 patients with DCIS who subsequently developed early-stage (I, II, or IIIa), ER+ IBC
between 2004 and 2015, 1184 (23.5%) had 21-gene
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TABLE 4. Multivariable-Adjusted HRs for Higher Levels of 21-Gene Recurrence Scores for Early-Stage,
Hormone Receptor–Positive Invasive Breast Cancer Among Women With DCIS in SEER, 1990-2015
Recurrence Scores
<18
Person-y
White
Black
Asian
Hispanic

1,018,475
129,931
128,657
102,614

≥18

Cases, No. HRa (95% CI) Cases, No.
421
58
77
50

1.00
421
1.11 (0.84-1.46)
68
1.37 (1.07-1.75)
57
1.17 (0.87-1.57)
32
P heterogeneity = .046

<26

≥26

HRa (95% CI) Cases, No. HRa (95% CI) Cases, No. HRa (95% CI)
1.00
1.29 (1.00-1.67)
0.97 (0.73-1.28)
0.71 (0.50-1.02)

602
84
97
64

1.00
240
1.13 (0.90-1.42)
42
1.19 (0.96-1.48)
37
1.03 (0.80-1.34)
18
P heterogeneity = .057

1.00
1.38 (1.00-1.92)
1.11 (0.78-1.57)
0.71 (0.44-1.14)

Abbreviations: CI, confidence interval; DCIS, ductal carcinoma in situ; HR, hazard ratio; SEER, Surveillance, Epidemiology, and End Results.
a
Hazard ratios were adjusted for the following: age (20-39, 40-49, 50-59, 60-69, or ≥70 years) and year of the primary DCIS diagnosis (1990-1999, 2000-2009,
or 2010-2015); treatment for primary DCIS (no surgical treatment, breast-conserving surgery alone, breast-conserving surgery followed by radiation therapy,
mastectomy, or unknown); and histopathological features of primary DCIS, including the tumor size (<2 cm, 2-5 cm, ≥5 cm, or unknown), grade (well differentiated, moderately differentiated, poorly differentiated, or unknown), histology (comedo, papillary, cribriform, solid, or not otherwise specified), and hormone
receptor expression (positive, negative, or unknown).

recurrence scores. There was no significant racial
difference in the use of 21-gene assays (Supporting
Table 3). Recurrence scores varied by race/ethnicity
(Pheterogeneity = .046-.057; Table 4). In comparison with
white women, the risk of subsequent ER+ IBC with a
recurrence score of 26 or higher was increased in black
women (HR, 1.38; 95% CI, 1.00-1.92). Using the
developed cutoffs for intermediate and high recurrence
risk, we observed a similar result for black women (HR,
1.29; 95% CI, 1.00-1.67). There was no significant difference in Asian and Hispanic women in comparison
with white women in the risk of developing aggressive
ER+ IBC defined by recurrence scores.
DISCUSSION
Our prior analysis of the 1990-2009 SEER data demonstrated a significantly higher risk of subsequently
developing IBC in black women with DCIS than white
counterparts.5 Using immunohistochemically assessed
tissue markers and 21-gene recurrence scores, the current
study extends this finding to biologically aggressive IBC
in a population-based, racially diverse group of patients
with DCIS. Compared with white women, black women
had a higher risk of developing IBC characterized by
ER–PR– subtypes and higher recurrence scores in ER+
tumors after DCIS. This is consistent with the higher risk
of developing ER–PR– IBC in the general population of
black women.13,22,23 Asian women were more likely than
white women to develop ER–PR– IBC. To our knowledge, this is the only study to date examining racial differences in subsequent IBC subtypes after DCIS.
Our finding of a higher risk of developing aggressive
breast cancer in black women with DCIS in comparison
3230

with white counterparts may have clinical relevance.
Black women with DCIS are more likely than white
counterparts to die of breast cancer.11 In the setting of
IBC, basal-like tumors disproportionately affect African
American women.13,22,23 Basal-like tumors overlap
largely with triple-negative tumors, which have a poor
prognosis. Most ER–PR– breast cancers (73%) are negative for HER2.16 We observed that the risk of triplenegative breast cancer was nearly doubled after DCIS in
black women compared with white women. Therefore, a
higher risk of developing ER–PR– IBC in black women
with DCIS may contribute to their worse survival.
Two distinct types of ipsilateral breast cancer
recurrence have been proposed: true local recurrences
and new ipsilateral primary tumors.17,24,25 They are generally distinguished from each other on the basis of both
histopathology and location.17,26,27 True recurrences have
a histopathology similar to that of primary tumors and
are close to the primary tumor bed. True recurrences may
reflect regrowth of clonogenic cells that have not been
completely removed by local treatment. New primary
IBCs are independent of the original breast cancer and
have different clinical features and a different prognosis than true recurrences.17,26,27 The development of new
primary IBC has been considered a result of a genetic
predisposition to breast cancer and is associated with
higher occurrences of contralateral IBC.28 We observed
that the risk of developing IBC in the ipsilateral breast
away from the original DCIS and contralateral breasts,
particularly hormone receptor–negative subtypes, was
significantly increased in black women. This indicates
an underlying genetic susceptibility to breast cancer,
early-life behavioral exposures, and/or their interactions
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in black women. Prior studies demonstrated that patients
with true local recurrence had worse survival than those
with new ipsilateral primary IBC.26,27 Our finding of
a higher risk of developing ipsilateral IBC in the same
quadrant of the breast in black patients may contribute
to their worse survival. Molecular assays (eg, a loss of
heterozygosity) are more reliable approaches for showing
clonal relationships between original tumors and ipsilateral IBCs and for distinguishing genetically related
recurrences from genetically distinct new primaries.24,25
Racial differences in the distinct types of ipsilateral IBC
need to be confirmed with molecular methods.
The 21-gene recurrence score is an assay based on
reverse transcription–polymerase chain reaction that is
currently applied to early-stage, ER+ IBC to assess the
prognosis and the likely benefit from chemotherapy in
addition to endocrine therapy.29 Using the TAILORxdefined cutoff value of 26,19 we observed that black
patients with DCIS were more likely than white counterparts to subsequently develop aggressive ER+ IBC. Using
commonly used definitions of intermediate (18-30) and
high recurrence risks (≥31) generated a similar result.
This finding was consistent with the racial difference in
RNA expression–based recurrence scores reported for
first primary IBC.13-15 A recent analysis of TAILORx
trial data (including 8189 whites, 693 blacks, 405
Asians, and 432 others) showed a similar distribution of
recurrence scores across race groups in patients with
early-stage, hormone receptor–positive, HER2– IBC
(with no prior diagnosis of DCIS) and worse survival for
black patients.30 Our finding needs to be confirmed in
future studies with a larger number of black patients with
DCIS who have 21-gene assay results for subsequent IBC.
Biological differences (other than intrinsic subtypes)
between IBC in black women and white women have been
identified. In a comprehensive analysis of genomic, transcriptomic, and proteomic data from the Cancer Genome
Atlas, Huo et al31 found that a number of molecular features differed between black and white IBCs after adjustments for age and subtypes, including the DNA copy
number, gene expression, and DNA methylation. Gene
expression profiling of luminal A and basal-like IBCs identified 6 genes that were differentially expressed between
black and white patients and were also associated with
survival.32 In that study, some poor outcome–associated
genes were upregulated in cancer-adjacent normal breast
tissue from black women versus white women. Our data are
consistent with the idea that black women exhibit genetic
profiles in nascent tumor cells and/or surrounding normal cells that create a race-associated biological difference.
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This race-associated genetic difference may occur at the
earliest stages of carcinogenesis.
We observed a higher risk of developing ER–PR–
IBC in Asian women with DCIS than white counterparts. The clinical relevance of this finding remains to
be determined because there were no survival differences
between Asians and whites among patients with DCIS
from SEER.11 Within Asian American women with their
first primary IBC, distributions of ER–PR– subtypes have
been reported to vary across ethnic groups, with the highest frequency in South Asians and the lowest frequency in
Japanese and Chinese.33,34 The number of Asian patients
with DCIS with subsequent IBC did not allow us to
examine ethnic differences among Asian women.
This study has limitations. Some variables influencing DCIS outcomes (eg, surgical margins and endocrine
therapy) were unavailable. Prior studies reported no racial
differences in surgical margins or endocrine therapy in
patients with DCIS.6,9,35,36 Among those who initiated
endocrine therapy, blacks were more likely than whites to
be nonadherent to therapy, and Asians were more likely
to continue therapy.37 Obesity and alcohol consumption
have been associated with an increased risk of subsequent
breast cancer in patients with DCIS.38,39 We were unable
to assess their contributions to racial differences in DCIS
outcomes. The duration of follow-up was longer in white
patients than racial minority patients. However, the
exclusion of patients diagnosed after 2010 did not significantly change the race-associated risks (Supporting
Table 4). Approximately 40% of DCIS cases had no hormone receptor data, and missing indicators were used in
the analysis. This approach has been demonstrated to
have no significant impacts on the estimated associations
between exposures and cancer outcomes when missingness is less than 50%.40 The finding of a race-associated
higher risk of ER–PR– IBC in all eligible patients was
consistent with a race-associated higher risk of the hormone receptor status changing from positive to negative
observed in a subgroup of patients who had complete
hormone receptor data for both DCIS and subsequent
IBC (Supporting Table 5). The 21-gene recurrence scores
were available for only 24% of patients with DCIS who
subsequently developed early-stage, ER+ IBC. Among
women with IBC who had no history of DCIS, black
race has been associated with underutilization of 21gene assays and higher recurrence scores.14,15 Therefore,
a higher risk of recurrence score–defined aggressive IBC
in black women with DCIS may reflect racial differences
in testing. However, there was no significant racial difference in 21-gene testing in our sample.
3231
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Overall, we provide evidence for a higher risk of subsequently developing aggressive IBC in black and Asian
patients with DCIS in comparison with white counterparts.
This gives us a better understanding of racial influences on
the risk of IBC after the diagnosis of DCIS and should
be considered in the management of DCIS. Although the
molecular and genetic features underlying this higher risk
remain undiscovered, we have now specified the biological context for studying these inherent racial differences.
Future work will assess its contribution to poorer survival
in black women with DCIS. A better understanding of
race-associated biological and nonbiological differences in
the progression of DCIS will help to distinguish high-risk
patients with DCIS from low-risk patients with DCIS and
improve personalized treatment to reduce the disproportionate burden of breast cancer in black women.
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